Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Additional large-scale federal funding would likely go to a vaccine that could be delivered in one dose or orally rather than via injection."
https://www.usatoday.com/story/news/2020/08/28/us-should-have-four-coronavirus-vaccines-phase-3-mid-september/5660584002/
bought my position in vxrt back, everything in this day and age is a gamble. IMO
couldn't stay out
bought half back.
what's the saying... moth to the flame.
always tough to sell a stock you
believe has potential, but have learned the hard way that the
bottom may be a ways off. will get back in with the proper news.
vxrt.
so then it will go the full
30 days and then the company will get a yes, a no, or a
hold for more information, clarification.
well, with the guy kicking
the FDA's tail, it could be soon, if what they have, looks good.
soon would be the first few days of sept. IMO
what i have seen is the fda likes to go the full 30 days.
dew may have the most experience at this and the fda may just
ignore the noise.
IgA tech used by vaxart.
in their delivery system for c. v. 19
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719502/
pretty deep science for me, comments welcome, lol
should give them, with the cash
they have, about 20 mil in general funds and still keep the
float below or about 20 mil.
should add they are trading in the 3.60 range.
thanks for posting that film.
some more info.
https://pharmashots.com/press-releases/relief-therapeutics-and-neurorx-expand-clinical-trial-of-rlf-100-to-all-patients-with-critical-covid-19-and-respiratory-failure/
htbx aug 13 info.
they have been selling stock, atm.
some belief that their cash balance is somewhere around 150-200 mil.
os is up, perhaps around 150-175 mil.
https://www.heatbio.com/news-media/news-releases/detail/669/heat-biologics-covid-19-vaccine-demonstrates-robust-t-cell.
believe its called selling your product,
or something along those lines, lol.
but i do hope it will work, in fact it may take two or three
years before anyone know what works or works best.
dew, no not really, most i have seen before.
just have to wait and see what happens. they filed the
ind, suppose now wait for approval. heres some more if it works.
vxrt presentation 8/12/20.
https://investors.vaxart.com/static-files/76ded565-e448-4d98-910c-f1ae3629789c
abus up A H for
what its worth. last about 4.00
Added some eyen.
may drop more, like the low float, revenue possible.
any comments pro or con.
two billion shares, high market cap already.
https://www.businesswire.com/news/home/20200715005954/en/%C2%A0NeuroRx-Relief-Therapeutics-Announce-Data-Monitoring-Committee
a cut to payroll taxes
is a cut to SS and medicare, which pay a great share of drug
cost.
close to 35-40 % of a person's ss income goes for insurance
and drug cost.
payroll tax, which is already under heavy pressure, with a cut,
would be a direct cut to bios and the pharmaceutical industry.
IMO
sean tucker cso of vasart
along with others, conference on vaccines
https://www.arena-international.com/vaccine-virtual/agenda
asymptomatic or pre-symptomatic
https://www.msn.com/en-us/health/medical/even-asymptomatic-people-carry-the-coronavirus-in-high-amounts/ar-BB17ElBR?ocid=msedgdhp
IMO mask mandates are perhaps at this stage, the best protection the
human race has.
two high risk c. v. stocks
https://www.fool.com/investing/2020/08/03/2-risky-coronavirus-stocks-that-could-make-you-fil.aspx
perhaps they will reach an agreement sometime down the road,
if the vaccine works.
they are closed lip on the mixture of the delivery system, which is understandable,
considering how many eyes are on them worldwide.
remember abus felt they were owed "low single figure royalties"
which could change with events. IMO.
perhaps a repeat of amrn,
a few years down the road.
https://www.forbes.com/sites/nathanvardi/2020/07/29/modernas-mysterious-coronavirus-vaccine-delivery-system/#32403cc662d9
tnxp getting a little movement.
low of the day 1.06
close 1.34
after hours 1.41
never know about afterhours or pre...IMO
astra-to-pay-daiichi-up-to-six billion
https://www.msn.com/en-us/money/companies/astra-to-pay-daiichi-up-to-dollar6-billion-for-new-cancer-drug/ar-BB17ehRD?ocid=msedgdhp
my understanding is that there is no infringement until a
company sells the product.
correct me if wrong.
thanks dew, looks
like a wide open race to the finish line for the those companies
in the c. v. vaccine hunt.
suppose its only logical to expect the big companies to have the best
shot, still holding two or three of the small ones.
from former post.
Still, experts say that's no cause for panic, since our body's immunity isn't just tied to antibodies. White blood cells have an impressive immunological memory that can help the body identify and attack the invading virus should it ever return. T cells can destroy infected cells, and B cells work to produce new antibodies. A vaccine could help create both.
any comments on which company's vaccine might help in this area,
t-cells, b-cells.
perfect vaccine would be 100% effective at preventing viral infections. But no vaccine developer expects this to be the case with COVID-19. The US Food and Drug Administration has said it wants to see at least 50% effectiveness before it approves a shot.
they might drop that % for one with few side effects, IMO.
https://www.msn.com/en-us/health/medical/don-t-hold-your-breath-for-a-coronavirus-vaccine-here-are-the-7-biggest-challenges-we-still-need-to-overcome/ar-BB17b96U?ocid=msedgdhp
agreed.
same i would guess as telling someone not to do something.
sorry, should of said IMO
would be interested in your view of %, or any other
board member.
there were people against masks in 1918, so i guess its
nothing new. suppose we all have a little ant-establishment.
https://www.msn.com/en-us/money/markets/investors-cheer-as-two-coronavirus-vaccine-candidates-report-t-cell-responses-but-findings-are-still-early-stage/ar-BB16YuTm?ocid=msedgdhp